Enleofen Bio Pte
-
2017 April 01
Company Description
Enleofen is developing first-in-class antibody therapeutics to treat fibrosis
We are developing new anti-fibrotic therapies based on breakthrough science. Enleofen aims to have its lead antibody in clinical trials within a two year time frame with the goal of developing a drug that can be used to treat multiple diseases for which there are currently no treatment options.
-
Manufacturer:
Science and Engineering -
Formed:
April 1, 2017 -
Company Website:
-
Company E-mail:
-
Company Address:
Singapore -
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits